… thyroid cancer, particularly in papillary thyroid cancer (PTC). Excessive activation of BRAF/MAPK
signaling pathway due to BRAF mutation … The rather aggressive initial treatment in this …

… status and several clinicopathologic characteristics of high-risk disease, but limited
evidence that the mutation correlates with more extensive or aggressive disease. This analysis …

… between BRAF mutation and more aggressive tumor … BRAF mutation and more aggressive
tumor behavior is limited to older patients, and therefore BRAF as a marker of aggressive …

… BRAF mutation and clinicopathologic features of the tumors. We did not see an age or sex
preference of the BRAF mutation … advanced tumor stages (III/IV) and the BRAF mutation status …

… Whether the BRAF V600E mutation related to more aggressive clinicopathologic features
and worse outcome in PTC remains variable and controversial. We aim to investigate the risk …

… promoter mutations, particularly the C228T mutation, in thyroid … mutation to be associated
with the BRAF V600E mutation and … highly prevalent in aggressive types of thyroid cancer, such …

… This last possibility, in our opinion, could be a plausible explanation why our results do
not appear to confirm any particular aggressiveness in our cancer cases with BRAF V600E …

… In the present study, a patient with co-existence of BRAF V600E and GRIN2A L649W
mutations had aggressive features such as tracheal invasion and bilateral neck lymph node …

… Numerous studies reported a positive association between the BRAF V600E mutation and
features of aggressiveness in PTCs.47-57 In 2005, a multicenter study described a significant …

… Our findings therefore suggest that the BRAF V600E mutation is indeed associated with
aggressive phenotype and may be an independent marker for recurrent or persistent disease for …